Various investigations have shown that nutraceuticals are capable of fulfilling neuroprotective functions on molecular mechanisms that trigger AD, acting as antioxidants or anti-neuroinflammatory drugs, taking effect on the aggregation of β amyloid peptides, the hyperphosphorylation of the Tau protein and the decrease of the neurotransmitter ACh in cholinergic neurons [70,71,72]; such evidence allows us to project a scenario where AD could have possible preventive treatments and/or have a slowing palliative effect in patients who already suffer from it [73,74,75]. This evidence concerns the gene MAPT and Alzheimer disease.